

A recent update on Oral Anticoagulants

Abstract :

Atrial Fibrillation is very common among Americans; it is the irregular rhythm of the heart usually present with or without symptoms. It causes the formation of clots, clots go to the brain and cause a stroke. Anticoagulants have been known for a few decades to cause abrupt decrease around 50% in the rate of stroke and prevent clotting at the required location and can cause bleeding. Anticoagulants aim for the safeguard and therapy of thromboembolism to prevent stroke. Previously used Anticoagulants are Warfarin, low molecular weight heparin and heparin. There were shortcomings of the drugs like parenteral route of administration, requires frequent monitoring due to variability in response, the onset of action is slow and there is bleeding in response to the drugs. In addition to heparin and vitamin K antagonist, anticoagulants that act on enzymatic activity or vigor brought about by thrombin and factor Xa were exquisitely formulated. Implementation of the forementioned oral Anticoagulants requires knowledge of necessitate the comprehension of discrete indication, contraindications, characteristics. Research and repeated clinical trials have led to acceptance of few newer drugs which are working classically styled but better than Warfarin. In the last few years, Pradaxa (dabigatran), Xarelto (rivaroxaban), and Eliquis (dabigatran) have all been authorised by the FDA (apixaban). All three are 'blood thinners,' like warfarin, that lessen the overall risk of stroke associated with atrial fibrillation while also causing bleeding.

Keywords: non vitamin K antagonist, drug interactions, Thrombolytics, oral anticoagulants, Direct thrombin inhibitors

Introduction :

Nonvitamin K antagonist oral anticoagulants or initially called as Novel oral anticoagulants now designated or denominated as Direct oral anticoagulants are better alternative to vitamin K antagonist. (1). By convention, oral anticoagulants means warfarin like drugs which acts by interfering in the synthesis of clotting factor(1). The mechanism of clotting happens by two methods: vasoconstriction of the bleeding vessel to reduce the amount of blood loss and formation of platelet plug at the site of bleeding. Platelet comes together and also activate a phenomenon of formation of fibrin clots. Clot formation is a series of sequential reaction in which one step is activated by the reaction of previous. It occurs through two pathways extrinsic and intrinsic.(2)

The activation of extrinsic mechanism is triggered by trauma instigating blood to exclude out of enclosed vascular system .(2) This is a faster alternative to the intrinsic approach. In this procedure, Factor VII activate the intrinsic route, which is started by vascular damage(3). This is a more time-consuming procedure that includes components XII, XI, and IX.

Although these processes are often described separately ,many of them overlap between platelets procoagulant factors endogenous anticoagulants and fibrinolytic factors and endothelium to promote appropriate level of hemostasis and limit the formation of clot at vessel site.

The direct thrombin inhibitors along with direct factor Xa inhibitors impede utmost procoagulant action implicated in the genesis of a fibrin clot (4). Thrombin is the final effector being the concluding blood coagulation and factorX anchored at the intersection of extrinsic and intrinsic mechanism of coagulation constitute good targets for anticoagulation(5). On addition to that , Dabigatran by inhibiting fibrin bound thrombin and rivaroxaban,apixaban by inhibiting FXa assembled within the prothrombin ase complex have efficacy advantages over indirect thrombin inhibitors (heparin or low molecular weight heparin) and indirect FXa inhibitors (fondaparinux) respectively.(6)(3)

Therapy using heparin curtails the incidence of non-lethal and catastrophic PE by safeguarding thrombus expansion. In venography trials, however, complete clot lysis with therapy was identified in lower than 10% of acute DVT population or mass following therapy or the medication.(7).Unfractionated heparin (UFH) was the benchmark for first therapy. Without the use of an switching on partial thromboplastin time monitor, LMWH can be given subcutaneously once or twice a day. LMWH also has a decreased degree of heparin-incipited thrombocytopenia . Fondaparinux is a highly specific synthetic restrain. Fondaparinux is a factor Xa inhibitor.(8)(3)

Drawbacks

They're induced by UFH's nonspecific protein binding, and LMWH has a smaller molecular charge, therefore they're less common. Osteoporosis can develop with extended period utility UFH or LMWH medication. This isn't a practical joke. Most DVT patients only require short-term treatment, thus this isn't a major concern; however, though persistent usage of heparin can lead to drastic osteoclasts.(3)

Oral anticoagulants (OAC)

Amidst the previously 6 decades, the only orally acting vit . K antagonists (VKAs) have been coumarin derivatives such as warfarin and acenocoumarol. (9) Warfarin safeguards the cyclic modification of vit . K epoxide to vitamin K hydroquinone by suppression of the enzyme vit . K epoxide reductase (VKOR) (reduced form)(10). The liver's making of vit .k-dependent coagulation factors II, VII, IX, and X is diminished when this enzyme is blocked. Due to its structure (racemic mixture) and pharmacokinetic (PK) characteristics, warfarin is particularly sensitive to drug interactions (hepatic metabolism, strong protein binding). The two isomers of warfarin are S-isomer and R-isomer.,with the "S" form being more powerful. Cytochrome P(CYP)2C9 (S-isomer) and CYP1A2 and 3A4 (R-isomer) isozymes are the primary metabolizers of both isomers.

Warfarin has various drawbacks, including delayed onset and off-set of effect (due to factor II's lengthy half-life), drug–drug interactivity , and genetic polymorphism that causes varied sensitivity .It's also susceptible to a variety of drug–food interactions.(11). Over-the-counter

pharmaceuticals such as drugs (NSAIDs)/tramadol, as well as alternative herbal products/foods such as garlic and fenugreek, may exacerbate the anticoagulant activity of the VKA and cause bleeding. Warfarin, like other VKAs, has a number of drawbacks that make it difficult to utilise in clinical practise:

Action takes a long time to start and stop.

Unpredictable behaviour

Therapeutic window is limited.

Dose changes on a regular basis

Coagulation testing is done on a regular basis.

There are a lot of drug–drug interactivity (12)

There are a lot of food–drug interactivity(12)

Bleeding inside the skull

VKORC1 genetic variants and warfarin resistance CYP 2C9

Half-life is very long .If you don't start with LMWH, you'll get kin necrosis.

Apixaban

Apixaban is a selective direct restrain of factor Xa .Half-life is attained after 10 to 14 hours(8). Apixaban is partially assimilated and catabolized by CYP3A4; it is partially disposed off by the kidneys (25 percent) and partially handled by CYP-independent mechanisms in the liver. Apixa-1,2Ban is expected to be safe because it has no effect on CYP enzymes. Drug-drug interactivity are extremely unlikely. It's still a question mark. To see if it's possible to combine hepatic and renal elimination. It can be given to adults with benign safely.

Dabigatran etexilate

Dabigatran is a selective direct thrombin inhibitor(8). Dabigatran etexilate (a pro-drug) is quickly metamorphosed to dabigatran etexilate succeeding oral intake (a drug).At a peak dose of 500 mg, dabigatran (administration and hepatic processing) .Plasma concentrations of dabigatran were tested for around 1.5 hours.Oral intake comes next. Labels that have been approved once you've reached a state of equilibrium. Canada and other countries recommend an capricious decrement of dosage in the case of mild renal failure, but not in the case of severe renal problems.

The first NOAC was accredited by the EU in 2008, and the FDA approved it in 2009.(13)Dabigatran suppresses both free and clot-bound thrombin in a direct manner. Succeeding oral intake, dabigatran etexilate (a pro-drug) is swiftly transformed to dabigatran etexilate (a drug)(14).Dabigatran (administration and hepatic processing), at a peak dose of. Dabigatran plasma concentrations were measured for around 1.5 hours.

Following oral intake. Once you've reached a condition of equilibrium, Labels that have been approved

In the case of moderate renal failure, Canada and other countries propose an capricious decrement of dosage, but not in the case of severe renal dysfunction.

Dabigatran is an oral direct thrombin inhibitor that averts clot assembly by preventing fibrinogen to fibrin conversion. It is used amongst the individuals mass with NVAF the pertility to advance to stroke and systemic embolism. (15) The term “nonvalvular AF” is debatable and not easy to distinguish from “valvular AF.” It differs from one experiment to the next.[9] (3)

It is a prodrug (dabigatran etexilate) that is briskly transformed to dabigatran in the liver by enzymatic retroactions upon oral administration. It can be administered either beside food or not accompanied by food. It has a half-life of 12–14 hours and is dose-severign . Dabigatran, unlike VKA, its dosage response is predictable. In humans, the kidneys are the principal route of elimination for dabigatran (80 percent). As a result, conventional clinical practise recommends assessing renal function by measuring creatinine clearance prior to starting dabigatran.

There have been various studies comparing the sequela of dabigatran (110 mg) with warfarin, and the RE-LY study found that dabigatran is not subservient to warfarin in preventing stroke and systemic embolism in individuals with NVAF. Dabigatran was contrary to warfarin in this study, and both were linked to equal degree of stroke and systemic embolism. There were as well as fewer cases of serious bleeding . Furthermore, as contrast to warfarin, a greater dose of dabigatran (150 mg) was linked with lower degree of stroke and systemic embolism, but identical rates of severe bleeding.(16) Dabigatran also lowered the degree of ischemic stroke, cerebral bleeding, and a variety of other complications.

In the RE-COVER trial, individuals therapied with dabigatran (150 mg twice daily) had a risk of recurrent VTE of 2.4 percent, compared to 2.1 percent in those treated with warfarin. (3).These findings revealed that dabigatran was non subservient to warfarin in preventing reappearing VTE. the results of both studies have been compiled. In the RE-LY trial, one among the chief customary is non-bleeding side effects of dabigatran was gastroesophageal reflux disease-like symptoms with abdominal consert, which led to therapy discontinuation.

After oral administration and hepatic processing, dabigatran etexilate (a pro-drug) is briskly converted to dabigatran, with Plasma dabigatran peaking at magnitude of volume measured 1.5 hours later.Following oral intake. Dabigatran has a half-life of 12 hours once it reaches steady state.In the range of 14 to 17 hours. Bioavailability is 7.2 percent with oral therapy, and The majority of dabigatran is eliminated in the stool.3,4 Despite the fact that The bioconversion of a prodrug to an active metabolite takes place in The cytochrome p450 system in the liver ain't embroidered. Supposedly Quinine/quinidine and verapamil have significant pharmacological interactions.Have been described in detail. After hepatic absorption, dabigatran is eliminated.switching on takes place place.

Rivaroxaban

Rivaroxaban, a direct factor Xa inhibitor, compasses peak plasma levels three hours after being taken orally. Subsequent to attaining an unfluctuating stance , the concluding half-life is 4 to 9 hours (up to 12 hours iE rates in the conglomerated potency termination mark of cardiovascular arrest, noncatastrophic heart attack, griveous recurrent ischemia, etc.). 1st Table: Agent Company Status, phase degree in the composite effectiveness endpoints of cardiovascular death, nonlethal heart attack, and griveous reappearing ischemia

Indications and contraindications:

Oral anticoagulants that aren't vitamin K antagonists are licenced for stroke safeguard in non-valvular atrial fibrillation, minor to modest mitral stenosis, and rheumatic mitral stenosis.(1). It is utilised in the treatment of transaortic valve intervention. However, the use of a mechanical prosthetic valve negates the need for NOAC therapy. NOAC trials encompass minor to modest additional native valvular disease, such as aortic stenosis or regurgitation, degenerative mitral regurgitation, and so on. If the Bioprosthetic valve has been in place for more than 3 months and the patient has retrogressive mitral regurgitation or is in the array of aorta , NOAC therapy is allowed. TAVI and PTAV may need to be combined with a single or dual antiplatelet therapy.

There are scant data on hypertrophic cardiomyopathy, although patients may be candidates for NOACs.

anticoagulant and antiplatelet medications like aspirin is normally dodged in clinical practise, however there are a few exceptions, such as:

In masses afflicted by Coronary artery ailments who further more appertain under the 75 yr age cluster , for auxiliary vigilance of ischemic heart ailments .Antiplatelet medications, such as aspirin or clopidogrel, or both, are used after a percutaneous procedure (PCI). Ailing individuals bearing mechanical valves who are imputed to escalated perility of cerebrovascular setback because of specific or sole amongst the succeeding:

Dysfunction of the left ventricle

Caged ball or caged disc valves, collateral atrial fibrillation, left atrial augmentation. (7). NOAC therapy contraindications* Hypersensitivity is well-known(3)(7). Renal insufficiency: dabigatran (Pradaxa). Apixaban (Eliquis) Rivaroxaban (Xarelto) (rivaroxaban may be used to prevent VTE . Active bleeding that is clinically significant Significant bleeding disorder, either inherited or acquired Coagulopathy in hepatic disease Organ lesions with an inflated probability of hemorrhage, such as cerebral haemorrhage in the past six months .

Contraindications for NOAC therapy*

NOAC therapy contraindications*

Hypersensitivity is well-known.

Renal insufficiency

Knee replacement surgery (TKR)

Active bleeding that is clinically significant[9-12]

Significant bleeding disorder, either inherited or acquired

Coagulopathy in hepatic disease

Organ lesions with a inflated probability of hemorrhage , such as cerebral haemorrhage in the past six months

During the first 6 hours after removing an indwelling spinal or epidural catheter

Heart valve that is mechanical

Management of bleeding on NOAC :

Bleeding rates with NOACs are generally equivalent to or lower than bleeding rates with warfarin. NOACs do not have a specific antidote. NOAC should be stopped in the event of bleeding, and the hemodynamic stability, degree of anticoagulation, and severity of bleeding should all be assessed. Minor bleeding can be controlled by postponing the following dose.

The bleeding source might be treated to control upper or lower GI haemorrhage.

If diuresis is insufficient, RBC transfusion, platelet substitution, fresh frozen plasma as a plasma amplifier (certainly nevermore as a transposing conciliator), and dialysis may be scrutinized . Prothrombin complex, in addition to the other procedures, is used in deadly bleeding.

Women of childbearing age:

In female who pertain to reproductive age group outright Oral anticoagulant drugs implementation ought to be approached with extreme vigilance to exclude the likelihood of pregnancy and contraceptive counselling guidance .(13-17).

Most notably, NOACs are not recommended during pregnancy or breastfeeding.[18-23]

Conclusion :

Direct thrombin inhibitors and direct factor Xa inhibitors work at key sites in the coagulation cascade, which appears to be rate limiting in the development of clots. These medicines inactivated both circulation and clot-bound activated coagulation factor and did not produce antiplatelet antibodies, which could be beneficial in some therapeutic situations. Because there is less variability in pharmacological effects for a given dose, these agents have fewer need for monitoring and evaluation.

Over traditional anticoagulants, there is better patient compliance, easier management, and improved thromboprophylaxis. However, DOACs are costly, have a limited half-life, and are ineffective.

Depending on the creatinine clearance, patients with compromised renal function should have their doses reduced or avoided entirely. When switching anticoagulants, the goal is to keep the anticoagulation stable. When switching from a DOAC to a vitamin k antagonist, keep in mind that the full effect of the vka to a DOAC, keep in mind that the VKA effect may take several days to resolve.

Patient compliance, management, and thromboprophylaxis are all enhanced as compared to standard anticoagulants. DOACs, on the other hand, are more expensive than vit . k antagonists, have shorter half-lives, aren't appropriate for all indications, and compliance is more difficult to track and assess. They should be unaccustomed or unversed in people with grievous renal insufficiency, severe liver ailments, pregnancy, antiphospholipid syndrome, or a prosthetic heart valve. Before these drugs are given, the prothrombin time and set going /switch on partial thromboplastin time should be assessed. Prior to anticoagulation, coagulation status was tested and documented, and serum creatinine was quantified as a baseline and for possible dose adjustments.

COMPETING INTERESTS DISCLAIMER:

Authors have declared that no competing interests exist. The products used for this research are commonly and predominantly use products in our area of research and country. There is absolutely no conflict of interest between the authors and producers of the products because we do not intend to use these products as an avenue for any litigation but for the advancement of knowledge. Also, the research was not funded by the producing company rather it was funded by personal efforts of the authors.

References:

1. Chang PY, Wang W, Wu WL, Chang HC, Chen CH, Tsai YW, Chiou SH, Lip GY, Cheng HM, Chiang CE. Oral Anticoagulation Timing in Patients with Acute Ischaemic Stroke and Atrial Fibrillation. *Thromb Haemost*. 2021 Oct 14. Doi: 10.1055/a-1669-4987. Epub ahead of print. PMID: 34649296.
2. Rocio Hinojar, Jose Julio Jiménez-Natcher, Covadonga Fernández-Golfín, Jose Luis Zamorano, New oral anticoagulants: a practical guide for physicians, *European Heart Journal – Cardiovascular Pharmacotherapy*, Volume 1, Issue 2, April 2015, Pages 134–145, <https://doi.org/10.1093/ehjcvp/pvv002>
3. Batta A, Kalra BS, Khirasaria R. Critical Issues and Recent Advances in Anticoagulant Therapy: A Review. *Neurol India*. 2019 Sep-Oct;67(5):1200-1212. doi: 10.4103/0028-3886.271256. PMID: 31744944
4. Oliveira R, Patel RK, Taylor C, Czuprynska J, Arya R, Roberts LN. Direct oral anticoagulants for the management of venous thromboembolism in patients with HIV – a single centre experience. *Br J Haematol*. 2019 Sep;186(5):e148-e151. Doi: 10.1111/bjh.15986. Epub 2019 Jun 5. PMID: 31168830.
5. Weitz JL. Factor Xa and thrombin as targets for new oral anticoagulants. *Thromb Res*. 2011 Jan;127 Suppl 2:S5-S12. Doi: 10.1016/S0049-3848(10)70147-X. PMID: 21193114.
6. Furie K. Epidemiology and Primary Prevention of Stroke. *Continuum (Minneapolis)*. 2020 Apr;26(2):260-267. Doi: 10.1212/CON.0000000000000831. PMID: 32224751.
7. Lip GYH, Keshishian AV, Zhang Y, et al. Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients With High Risk of Gastrointestinal Bleeding [published correction appears in *JAMA Netw Open*. 2021 Sep 1;4(9):e2130836]. *JAMA Netw Open*. 2021;4(8):e2120064. Published 2021 Aug 2. Doi:10.1001/jamanetworkopen.2021.20064.
8. Wright State University Libraries / All Locations m-catalog.libraries.wright.edu > search~S7 > browse.Measuring electronic word-of-mouth effectiveness : developing and Treatment of non-vitamin K antagonist oral anticoagulants : for prevention of stroke.
9. Mekaj Y, Mekaj A, Duci S, Miftari E. New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. *Ther Clin Risk Manag*. 2015;11:967-977 <https://doi.org/10.2147/TCRM.S84210>

10. Siegal DM, Crowther MA. Acute management of bleeding in patients on novel oral anticoagulants. *Eur Heart J*. 2013 Feb;34(7):489-498b. doi: 10.1093/eurheartj/ehs408. Epub 2012 Dec 7. PMID: 23220847.
11. Fareed J, Thethi I, Hoppensteadt D. Old versus new oral anticoagulants: focus on pharmacology. *Annu Rev Pharmacol Toxicol*. 2012;52:79-99. Doi: 10.1146/annurev-pharmtox-010611-134633. Epub 2011 Aug 5. PMID: 21819239.
12. Ingrasciotta, Y.; Fontana, A.; Mancuso, A.; Ientile, V.; Sultana, J.; Uomo, I.; Pastorello, M.; Calabrò, P.; Andò, G.; Trifirò, G. Comparison of Direct Oral Anticoagulant Use for the Treatment of Non-Valvular Atrial Fibrillation in Pivotal Clinical Trials vs. The Real-World Setting: A Population-Based Study from Southern Italy. *Pharmaceuticals* 2
13. Reebye UN, Shroff D, Fortier K, Kirk Jr WS (2016) Novel Oral Anticoagulants: Comparative Pharmacology and Dental Implications. *Dent Health Curr Res* 2:3. Doi:10.4172/2470-0886.1000118
14. Kipshidze N, Dangas G, White CJ, Kipshidze N, Siddiqui F, Lattimer CR, Carter CA, Fareed J. Viral Coagulopathy in Patients With COVID-19: Treatment and Care. *Clin Appl Thromb Hemost*. 2020 Jan-Dec;26:1076029620936776. Doi: 10.1177/1076029620936776. PMID: 32687449; PMCID: PMC7461127.
15. Kimpton G, Dabbous B, Leach P. New oral anticoagulant and antiplatelet agents for neurosurgeons. *Br J Neurosurg*. 2015;29(5):614-21. Doi: 10.3109/02688697.2015.1029433. Epub 2015 Jun 3. PMID: 26037940.
16. Meyer Dos Santos S, Harder S. Benefit-risk assessment of dabigatran in the treatment of stroke prevention in non-valvular atrial fibrillation. *Drug Saf*. 2014 May;37(5):295-307. Doi: 10.1007/s40264-014-0151-1. PMID: 24683059.
17. Chavan, Gajanan Namdeorao, Akanksha Saurabh Aggarwal, Parwez Khan, and Ritu Mridul Sahi. "Awake Fiberoptic Assisted Nasotracheal Intubation in Oral Malignancies- A Comparison between Airway Blocks and LA Spray - A Randomized, Interventional Crossover Trial." *JOURNAL OF EVOLUTION OF MEDICAL AND DENTAL SCIENCES-JEMDS* 9, no. 34 (August 24, 2020): 2417–21. <https://doi.org/10.14260/jemds/2020/526>.
18. Deshpande, Meghana Ajay, Sudhindra Baliga, Sapna Randad, Nilima Thosai, and Nilesh Rathi. "Probiotic Bacteriotherapy and Its Oral Health Perspective." *JOURNAL OF EVOLUTION OF MEDICAL AND DENTAL SCIENCES-JEMDS* 9, no. 34 (August 24, 2020): 2479–83. <https://doi.org/10.14260/jemds/2020/538>.
19. Ghogare, Ajinkya Sureshrao, Sally John, Pradeep Shriram Patil, and Ganpatlal Kodarbhai Vankar. "Study of Iron Profile and Effect of Oral Iron Supplementation in Patients of Attention Deficit Hyperactivity Disorder in Rural Tertiary Health Care Centre from Central India: A Case Series." *JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH* 14, no. 10 (October 2020). <https://doi.org/10.7860/JCDR/2020/43748.14144>.
20. Goyal, Richa, Chandra Veer Singh, Shraddha Jain, Sana Parveen, Prasheelkumar Gupta, and Deepak Gupta. "Our Experience with Nasolabial Flaps in Soft Tissue Reconstruction of Oral Malignancy; Feasible Option in Rural Set Up." *INDIAN JOURNAL OF OTOLARYNGOLOGY AND HEAD & NECK SURGERY*, n.d. <https://doi.org/10.1007/s12070-020-02257-2>.

21. Gupta, Bharti, Shekhar Gupta, Minal Chaudhary, A. Thirumal Raj, Kamran Habib Awan, and Shankargouda Patil. "Oral Candida Prevalence and Species Specificity in Leprosy." *DM DISEASE-A-MONTH* 66, no. 7, SI (July 2020). <https://doi.org/10.1016/j.disamonth.2019.100920>.
22. Gupta, Bharti, Shekhar Gupta, Minal Chaudhary, A. Thirumal Raj, and Shankargouda Patil. "Cross-Sectional Observational Study Evaluating the Association between Odontogenic Cystic Content and Size." *ARCHIVES OF ORAL BIOLOGY* 120 (December 2020). <https://doi.org/10.1016/j.archoralbio.2020.104954>.
23. Gupta, Bharti, Shekhar Gupta, Minal Chaudhary, A. Thirumal Raj, and Shankargouda Patil. "Oro-Facial Manifestations in Lepromatous Leprosy Patients in Central India: Clinical Findings from a Cross-Sectional Study." *CLINICAL ORAL INVESTIGATIONS* 24, no. 6 (June 2020): 1981–86. <https://doi.org/10.1007/s00784-019-03061-1>.

UNDER PEER REVIEW